Home › Funds › DRIEHAUS CAPITAL MANAGEMENT LLC › XENE
DRIEHAUS CAPITAL MANAGEMENT LLC position in XENE
XENON PHARMACEUTICALS INC · Health Care
DRIEHAUS CAPITAL MANAGEMENT LLC reported holding 3,557,546 shares of XENE (XENON PHARMACEUTICALS INC) in its Q3 2026 13F filing — a position valued at US$132.3M, representing 0.92% of its reported portfolio and ranking #17 among its reported holdings. DRIEHAUS CAPITAL MANAGEMENT LLC has disclosed XENE holdings in 13 of the last 13 reported quarters, going back to Q3 2023.
Last updated: 2026-11-16 · Source: SEC EDGAR Form 13F-HR
How DRIEHAUS CAPITAL MANAGEMENT LLC's XENE position evolved
DRIEHAUS CAPITAL MANAGEMENT LLC first disclosed a stake in XENE in Q3 2023 at 4,513,005 shares (US$154.2M). The position peaked in Q2 2026 at 4,418,557 shares, worth US$266.7M. Across 13 filings, DRIEHAUS CAPITAL MANAGEMENT LLC increased the stake 4 time(s), trimmed it 8 time(s) and left it unchanged 0 time(s). The most recent filing (Q3 2026) shows 3,557,546 shares valued at US$132.3M — a reduction of -861,011 shares quarter over quarter..
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2023 | 4.51M | $154.16M | New |
| Q4 2023 | 4.35M | $200.14M | Reduce |
| Q1 2024 | 4.32M | $186.05M | Reduce |
| Q2 2024 | 4.42M | $172.32M | Add |
| Q3 2024 | 4.60M | $180.93M | Add |
| Q4 2024 | 4.52M | $177.21M | Reduce |
| Q1 2025 | 4.58M | $153.82M | Add |
| Q2 2025 | 4.34M | $135.71M | Reduce |
| Q3 2025 | 4.17M | $167.39M | Reduce |
| Q4 2025 | 4.54M | $203.42M | Add |
| Q1 2026 | 4.49M | $261.19M | Reduce |
| Q2 2026 | 4.42M | $266.70M | Reduce |
| Q3 2026 | 3.56M | $132.31M | Reduce |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About XENE and 13F data
XENE (XENON PHARMACEUTICALS INC) is a Health Care company. 31 other funds we track also report a position in XENE — the largest reported positions include Avoro Capital Advisors LLC (US$204.5M), DEERFIELD MANAGEMENT COMPANY, L.P. (US$97.5M), Affinity Asset Advisors, LLC (US$70.7M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding XENE
- Avoro Capital Advisors LLC 5.50M sh · $204.54M · Q3 2026
- DEERFIELD MANAGEMENT COMPANY, L.P. 1.62M sh · $97.52M · Q2 2026
- Affinity Asset Advisors, LLC 1.90M sh · $70.67M · Q3 2026
- BRAIDWELL LP 1.13M sh · $68.29M · Q2 2026
- ORBIMED ADVISORS LLC 892.47K sh · $53.87M · Q2 2026
- Caligan Partners LP 889.94K sh · $53.72M · Q2 2026
- Vestal Point Capital, LP 700.00K sh · $42.25M · Q2 2026
More on DRIEHAUS CAPITAL MANAGEMENT LLC
FAQ
How long has DRIEHAUS CAPITAL MANAGEMENT LLC held XENE?
DRIEHAUS CAPITAL MANAGEMENT LLC has disclosed XENE holdings in 13 of the last 13 reported quarters, going back to Q3 2023.
What is DRIEHAUS CAPITAL MANAGEMENT LLC's current position in XENE?
As of Q3 2026, DRIEHAUS CAPITAL MANAGEMENT LLC holds 3.56M shares of XENE (XENON PHARMACEUTICALS INC), valued at $132.31M, representing 0.92% of its reported portfolio and ranking #17.
Has DRIEHAUS CAPITAL MANAGEMENT LLC been buying or selling XENE?
In the latest 13F filing (Q3 2026), DRIEHAUS CAPITAL MANAGEMENT LLC reduced its position in XENE. The position peaked in Q2 2026 at 4.42M shares.
Which other funds hold XENE?
Other major institutional holders of XENE include Avoro Capital Advisors LLC, DEERFIELD MANAGEMENT COMPANY, L.P., Affinity Asset Advisors, LLC, among 31 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.